Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04871360
Other study ID # NAFLD-CITRULLINE
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 5, 2021
Est. completion date January 15, 2022

Study information

Verified date January 2022
Source Universidad de Guanajuato
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

One of the comorbidities of obesity is nonalcoholic fatty liver disease (NAFLD). L-citrulline is a non-protein amino acid that has shown positive effects on the degree of fat retention and metabolic profile in NAFLD. The objective is to assess the effect of oral L-citrulline supplementation on liver function and nonalcoholic fatty liver in adolescents with obesity. A clinical study will be carried out in 40 adolescents (15-19 years) with obesity, they will be divided into a control group that will receive a placebo and an experimental group that will receive 6 g of l-citrulline per day for eight weeks.


Description:

It is hypothesized that l-citrulline supplementation decreases liver enzymes and the degree of hepatic steatosis in adolescents with obesity. The aim of the study is to assess the effect of oral L-citrulline supplementation on liver function and nonalcoholic fatty liver in adolescents with obesity. A prospective randomized, double-blind clinical study will be carried out in 40 adolescents (15-19 years) with obesity, they will be divided into a control group that will receive a placebo (carboxymethyl cellulose) and an experimental group that will receive 6 g of pure l-citrulline per day per eight weeks. At the beginning and end of the intervention, anthropometric, biochemical and metabolic data will be evaluated, as well as tests of function and degree of hepatic steatosis.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date January 15, 2022
Est. primary completion date December 19, 2021
Accepts healthy volunteers No
Gender All
Age group 15 Years to 19 Years
Eligibility Inclusion Criteria: - Adolescents between 15 and 19 years old, residents of the city of León, Guanajuato, with obesity due to BMI =30 kg / m2 equivalent to the categorization of adults. That they are in stage 5 of Tanner scale with diagnosis of mild, moderate or severe NAFLD and / or alterations in liver enzyme levels. Not be under nutritional treatment, not be smokers, not taking multivitamins, if so, a wash time of 30 days will be given. Not be allergic to l-citrulline or watermelon. Alcohol consumption less than 21 standard drink units for men and 14 standard drink units for women per week (Standard drink: any drink with more than 14 g of pure alcohol). Exclusion Criteria: - Present intolerance to l-citrulline or allergy to watermelon. - Have an adherence of less than 80 percent of the treatments. - Present other causes of liver disease.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
L-Citrulline supplement
The intervention will consist of oral supplementation of six grams of pure l-citrulline for eight weeks.
Carboxymethyl cellulose supplement
The intervention will consist of oral carboxymethyl cellulose supplementation as a placebo.

Locations

Country Name City State
Mexico University of Guanajuato León Guanajuato

Sponsors (1)

Lead Sponsor Collaborator
Universidad de Guanajuato

Country where clinical trial is conducted

Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Degree of hepatic steatosis The degree of hepatic steatosis will be evaluated by abdominal ultrasound. It will be diagnosed as:
Mild, when an increase in echogenicity and hepatomegaly are observed.
Moderate, when sound attenuation is added.
Severe, when the wall of the portal vessels and the diaphragm are not visible.
Baseline to 8 weeks
Secondary Glucose Glucose will be evaluated by the GOD-PAD Lakeside glucose oxidase method. Baseline to 8 weeks
Secondary Insulin The insulin level will be measured by ELISA (ALPCO) method. The HOMA-IR index will be calculated to determine insulin resistance. Baseline to 8 weeks
Secondary Insulin resistance The HOMA-IR index to determine insulin resistance will be calculated from serum glucose and insulin levels. Baseline to 8 weeks
Secondary Lipid profile The lipid profile will be measured by the modified Huang method of the Spinreact brand. Baseline to 8 weeks
Secondary LDL-cholesterol LDL-cholesterol will be determined using the Friedwald formula. Baseline to 8 weeks
Secondary Urea levels Urea levels will be obtained by the Urease GLDH kinetic method. Baseline to 8 weeks
Secondary Uric acid levels Uric acid will be evaluated by peroxidase enzymes and colorimetry. Baseline to 8 weeks
Secondary Liver function Liver function will be evaluated using the liver enzymes alanine aminotransferase and aspartate aminotransferase by the UV enzymatic kinetic method, as well as with alkaline phosphatase by the optimized kinetic method and direct bilirubin by the DMSO method (dimethyl sulfoxide-Malloy-Evelyn reaction). Baseline to 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2